Dorixina Relax is recommended for the management of musculoskeletal pain, especially with muscle spasms.
Also read: Tackling 6 common misconceptions about the safety of medical marijuana
Contraindications
Dorixina Relax may not be used in persons with known hypersensitivity to lysine clonixinate or cyclobenzaprine, active stomach ulcer or gastroduodenal bleeding, pregnancy or in children and adolescents under the age of 15. It is also contraindicated in patients with a history of bronchospasms, nasal polyps, angioedema or urticaria caused by the administration of acetylsalicylic acid (aspirin) or other NSAIDs.
Due to the Cyclobenzaprine component, Dorixina Relax, contrary to the simultaneous administration with monoamine oxida inhibitors (Maois) or within 2 weeks after their stopping. Moreover, it must be avoided in persons with a recent acute myocardial infarction, heart failure, arrhythmia, heart block, guiding disorders or hyperthyroidism.
Pros and cons of Dorixina
Advantages of Dorixina Relaxing:
- Effective pain relief
- Double Mechanism
- Rapid absorption
Disadvantages of Dorixina Relax:
- Potential adverse effects
- Contraindications and precautions
- Risks
Differences between Dorixina and Flanax
Dorixina:
Working by inhibiting prostaglandine synthesis, which reduces pain and inflammation. Cyclobenzaprine, the muscle relaxation component, works centrally on the nervous system to relieve muscle spasms.
Flanax:
Naproxen sodium also inhibits prostaglandine synthesis, causes pain relief and reduction of inflammation.
Alternative to Dorixina
Muscle relaxants:
Alternative muscle relaxants for cyclobenzaprine in Dorixina are methocarbamol, tizanidine, baclofen and metaxalone. These drugs work by relaxing muscles and reducing muscle spasms.
Precautionary measures
If allergic skin and/or mucosal reactions or symptoms of stomach ulcer or gastrointestinal bleeding occur, stop treatment with Dorixina relaxed. The Cyclobenzaprine component can strengthen the depressive effects of alcohol, barbiturates or other CNS depressants. Caution is required for the administration of patients with a history of digestive diseases such as gastroduodenal stomach ulcer or gastritis and in patients treated with anticoagulants.
Although no cases have been reported with the administration of lysine clonixinate, NSAIDs inhibit the synthesis of prostaglandins, which play a supporting role in maintaining kidney perfusion. In patients with a reduced kidney blood flow, NSAID can cause kidney compensation, usually reversible when the product is stopped. Patients with the greatest risk include those who have dried out, congestive heart failure, liver cirrhosis, nephrotic syndrome or other kidney diseases, as well as those who take diuretics or who have undergone major operations that result in hypovolemia. In such patients, diuresis volume and kidney function must be followed before the therapy is started. Although not often observed during the treatment with lysine clonixinate, NSAID can increase the transaminase plasma levels or other liver parameters, although in most cases these increases are small and temporary.
Cyclobenzaprine, chemically related to tricyclic antidepressants and parasympatholytic medicines, must be carefully used in patients with a history of urine retention, glaucoma with angle housing, increased intraocular pressure (IOP) and in people who use anticholinergic drug.
Pediatric use of Cyclobenzaprine is contrary because there are no clinical studies available for children and adolescents under the age of 15.
In geriatric patients, such as other anti-inflammatory drugs, Dorixina Relax must be administered with caution as a result of possible damage to cardiac, liver or kidney functions.
Drug interactions
Other NSAIDs, including high doses of acetylsalicylic acid, increase the risk of gastroduodenal ulcers and bleeding because of their synergy effect.
Oral anticoagulants, ticlopidine, heparin (systemic administration) and thrombolytics are an important risk of bleeding when they are used simultaneously with Dorixina relaxed. If simultaneous administration is inevitable, strict monitoring of blood clotting is necessary, with adjustments to the dosage of medicines that affect the coagulation parameters accordingly.
Lithium levels are usually raised by NSAIDs, so close monitoring of lithium plasma levels is needed when starting, changing or stopping treatment with Dorixina relaxed.
Simultaneous use of methotrexate and NSAIDs can increase the hematological toxicity of methotrexate. In such cases, rigorous hematological monitoring is essential.
In patients who receive diuretics, the potential risk of acute kidney failure is increased by NSAID treatment, in particular in cases of dehydration. If lysine clonixinate and diuretics are administered simultaneously, patients must be adequately hydrated and monitor their kidney function before they initiate treatment.
During simultaneous therapy with antihypertensive agents and NSAIDs, a decrease in antihypertensive drugs was reported due to the inhibition of vasodiling prostaglandins.
The Cyclobenzaprine component can cause hyperpyretic crises and convulsions with a fatal outcome in interaction with Mao inhibitors. In addition, when simultaneously with guanethidine and similar connections, it can theoretically block their anti -hypertensive action.
Side effects
With therapeutic doses, Dorixina Relax is generally well tolerated. In rare cases, especially in sensitive people, this can lead to nausea, vomiting, gastritis and somnolence.
The combination with Cyclobenzaprine can lead to slaves, dry mouth and dizziness.
Less often, occurring in 1-3% of the cases, adverse effects can include asthenia, constipation, dyspepsia, unpleasant taste, blurred vision, headache and nervousness.
Side effects reported with an incidence of less than 1% include malaise; Tachycardia, arrhythmia, hypotension, heart palpitations; Anorexia, vomiting, diarrhea, abdominal pain, gastritis, thirst, flatulence and abnormal liver function.
In very rare cases, events such as hepatitis and cholestasis; Anaphylaxis, angio -edema, itching, facial edema or edema of the tongue, urticaria, rash; Ataxia, Vertigo, Dysarthria, Tremor, Hypertonia, Spierspasms, convulsions, disorientation, insomnia, depressive mood, anxiety, agitation, abnormal thinking and dreams, excitement, paraesthesia, diplopia; sweating; AGEUSIA, TINNITUS AND URINE REFULUE or RETENENTE have been reported.
Conclusion
Dorixina Relax is a medicine that is generally driven well with therapeutic doses, although rare side effects can occur, especially with sensitive individuals. The combination with Cyclobenzaprine can lead to extra side effects such as sleepiness, dry mouth and dizziness. Although most side effects are small and spontaneously solve, care providers must be vigilant for more serious reactions, albeit rare. As with any medicine, the benefits of Dorixina Relax must be weighed against the potential risks and patients must be closely monitored on signs of adverse effects during treatment.
References
Drugs.com. “Cyclobenzaprine: use, dosage and side effects.” drugs.com.
https://www.drugs.com/cyclobenzaprine.htmlMedlinePlus. “Muscle relaxants.” medlineplus.gov.
https://medlineplus.gov/musclerelaxants.htmlMayo Clinic. “Cyclobenzaprine oral route.” Mayoclinic.org.
https://www.moyoclinic.org/drugs-plements/cyclobenzaprine-oral
#Dorixina #Relax #dosage #side #effects #precautions